OAM
MTNB icon

Oxford Asset Management’s Matinas BioPharma MTNB Stock Holding History

Oxford Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,214
Closed -$251K – 882
2019
Q4 		$251K Buy
2,214
+1,904
+614% +$110K 0.01% 1490
2019
Q3 		$10K Buy
+310
New +$11.2K ﹤0.01% 1669
2018
Q3 		– Sell
-656
Closed -$14K – 1847
2018
Q2 		$14K Buy
+656
New +$19K ﹤0.01% 1666

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oxford Asset Management's MTNB Position: Q1 2020 in Review

Oxford Asset Management sold out of Matinas BioPharma (MTNB) in Q1 2020, closing a stake of 2,214 shares — an estimated $251K sold.

Oxford Asset Management first reported a position in MTNB in Q2 2018 and held it in 3 quarters. The position peaked at $251K in Q4 2019. 68 funds tracked by Wall St. Rank hold MTNB as of Q1 2020.

  • Oxford Asset Management reported no remaining Matinas BioPharma position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 2,214 Matinas BioPharma shares in Q1 2020, an estimated $251K.
  • Oxford Asset Management first reported a position in Matinas BioPharma in Q2 2018 and held it in 3 quarters.
  • Oxford Asset Management's Matinas BioPharma position peaked at $251K in Q4 2019.
  • 68 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.